

**Immunocore Ranked No 1 South East Company in the Annual Sunday
Times Hiscox Tech Track 100**

(Oxford, UK, 7 September 2015) Immunocore Limited, a world-leading biotechnology company developing novel T cell receptor (TCR) based biological drugs to treat cancer, viral infections and autoimmune disease, today notes that it has been ranked as the Number one company in the southeast region and number nine overall in the 15th annual Sunday Times Hiscox Tech Track 100.

The Sunday Times Hiscox Tech Track 100 league table ranks the top 100 private British technology, media and telecoms (TMT) companies with the fastest-growing revenues over the last three years. Immunocore appears in the league table for the first time as it has grown revenues exponentially to £6.4 million in 2014.

Tech Track 100 is compiled by Fast Track in association with The Sunday Times on an annual basis and adopts the London Stock Exchange's techMARK definition of a technology company as one 'that shows a commitment to innovation, research and product development, and operates in sectors including software, internet, telecoms and biotech'.

Eva-Lotta Allan, Chief Business Officer at Immunocore, commented: "We are delighted that our recent growth and performance has been recognised by inclusion in the prestigious Tech Track 100. TMT is one of the most exciting sectors in the UK and for Immunocore, which is a leading biotech company, to rank alongside some of the UK's fastest growing and most innovative companies is a great source of pride for us."

- ENDS -

For more information, please contact:

Immunocore

Eliot Forster, Chief Executive Officer

T: +44 (0)1235 438600

E: info@immunocore.com

Consilium Strategic Communications

Mary-Jane Elliott/Jessica Hodgson/Chris Welsh/Laura Thornton

T: +44 (0)203 709 5700

E: Immunocore@consilium-comms.com

IMMUNOCORE

targeting T cell receptors

Notes for editors

About Immunocore

Immunocore is one of the world's leading biotechnology companies, with a highly innovative immuno-oncology platform technology called ImmTACs. ImmTACs are a novel class of biologic drugs based on the Company's proprietary T cell receptor (TCR) technology which have the potential to treat diseases with high unmet medical need including cancer, viral infections and autoimmune diseases. Immunocore, based on decades of world-leading scientific innovation in the discovery of HLA targets and T cell receptor technology, has a pipeline of wholly-owned and partnered ImmTAC programmes with robust clinical data, validated by collaborations with world-leading pharmaceutical companies. Immunocore aims to leverage the utility of its platform across a wide range of indications to become a Premier Biotech company and world-leader in its field.

Immunocore's world-leading science and strong IP position has attracted major pharmaceutical companies including Genentech, GlaxoSmithKline, MedImmune, the biologics division of AstraZeneca, via discovery collaborations, as well as a co-discovery and co-development partnership with Lilly. The Company has also entered into combination trials with its lead programme, IMCgp100 in melanoma, with Medimmune and Lilly. Founded in 2008 originally out of Oxford University and headquartered outside Oxford, Immunocore now has more than 160 staff. Immunocore's current investors are well-renowned, leading international institutions including Woodford Investment Management, Malin Corporation, Eli Lilly and Company, RTW Investments, Fidelity Management & Research Company as well as other private shareholders. For more information, please visit www.immunocore.com

About ImmTACs

Immunocore's proprietary technology is focused on small protein molecules called ImmTACs (Immune mobilising mTCR Against Cancer) that enable the immune system to recognise and kill cancerous or bacterially/virally infected cells. Immunocore's ImmTACs, a new class of drug with ultra-high affinity for intracellular cancer targets, are synthetic, soluble T cell receptors (TCRs) that recognise diseased cells containing disease specific targets. The ImmTACs enable circulating T-cells to selectively identify and kill diseased cells. The ImmTAC platform is unique in its high specificity and potency and broad applicability to a wide range of intracellular targets and disease indications. ImmTACs

IMMUNOCORE

targeting T cell receptors

can access up to nine-fold more targets than typical antibody-based therapies, including monoclonal antibodies.

TCRs naturally recognise diseased cells and Immunocore's world-leading competitive advantage is its ability to engineer high affinity TCRs and link them to an antibody fragment that activates a highly potent and specific T cell response to recognise and destroy cancer cells. The most advanced ImmTAC, IMCgp100, is currently in Phase IIa clinical trials for the treatment of late stage melanoma. Immunocore has a growing internal pipeline of ImmTACs addressing many different cancer types and has developed a broad database of intracellular cancer targets.

ImmTACs can address a significantly larger range of disease indications than currently respond to existing immuno-oncology agents and combine the characteristics of very high potency, encouraging safety and low cost of goods.

Sunday Times Hiscox Tech Track 100

The Sunday Times Hiscox Tech Track 100 adopts the London Stock Exchange's (LSE) techMARK definition of a technology company as one 'that shows a commitment to innovation, research and product development, and operates in sectors including software, internet, telecoms and biotech'. Companies had to be registered in the UK and be independent, unquoted and ultimate holding companies. Companies were ranked according to the compound annual growth rate in sales over three years, based on their latest available figures (either 2011 to 2014, or 2012 to 2015). The research therefore carries the caveat that their performance may have changed since. Annualised sales had to exceed £250,000 in the base year (2011 or 2012) and £5m in the latest year (2014 or 2015). Companies also had to increase sales in the latest year, but did not need to be in profit. Pure computer resellers are excluded. The research was carried out by Fast Track principally between May and August. The majority of companies were interviewed by telephone or visited by the Fast Track research team.